- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.06. | EVMN Stock Tanks as Phase IIb Urticaria Study Misses Primary Goal | 1 | Zacks | ||
| 30.06. | Evommune stock downgraded by H.C. Wainwright after trial failure | 2 | Investing.com | ||
| 29.06. | Studien-Fehlschlag schickt Evommune Aktie auf Talfahrt | 7 | Investing.com Deutsch | ||
| 29.06. | Evommune's Skin Disorder Study Falls Short | 3 | Benzinga.com | ||
| 29.06. | Raymond James stuft Evommune nach gescheiterter Studie herab | - | Investing.com Deutsch | ||
| 29.06. | Raymond James cuts Evommune stock rating on trial miss | 2 | Investing.com | ||
| 29.06. | William Blair stuft Evommune Aktie auf 'Market Perform' herab | 2 | Investing.com Deutsch | ||
| EVOMMUNE Aktie jetzt für 0€ handeln | |||||
| 29.06. | Evommune stock rating cut to Market Perform by William Blair | 1 | Investing.com | ||
| 29.06. | Evommune's phase 2b trial flops, ending challenge to Novartis in hives | 12 | FierceBiotech | ||
| 29.06. | Evommune drops on phase 2 data for EVO756 in urticaria | 3 | Seeking Alpha | ||
| 29.06. | Evommune's EVO756 fails phase 2b trial in chronic urticaria | 3 | Investing.com | ||
| 29.06. | Evommune, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 02.06. | Evommune, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.05. | H.C. Wainwright reiterates Evommune stock rating on trial progress | 1 | Investing.com | ||
| 26.05. | H.C. Wainwright bestätigt Kaufempfehlung für Evommune nach Studienfortschritt | 1 | Investing.com Deutsch | ||
| 08.05. | Evommune übertrifft Verlustprognosen - Aktie legt zu | 4 | Investing.com Deutsch | ||
| 08.05. | Evommune, Inc. GAAP EPS of -$0.64 | 1 | Seeking Alpha | ||
| 07.05. | Evommune, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.04. | Evommune, Inc. - S-1, General form for registration of securities | - | SEC Filings | ||
| 17.04. | Evommune stock price target reaffirmed at $50 by H.C. Wainwright | 5 | Investing.com |
1 2 3 Weiter >>
53 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 6,398 | +7,75 % | Clinuvel Pharmaceuticals (ASX:CUV): Nearly 7 years on from the FDA's approval of Scenesse, this company is now at a crossroads | ||
| EDITAS MEDICINE | 2,910 | -9,06 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,880 | 0,00 % | Cardiol Therapeutics Inc. - 6-K, Report of foreign issuer | ||
| ATAIBECKLEY | 4,740 | +4,41 % | AtaiBeckley Inc.: AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder | 156 patients randomized in multi-center, double-blind, placebo-controlled Phase 2b Elumina trial; topline data anticipated in Q4 2026 (ClinicalTrials.gov: NCT06524830)AtaiBeckley plans to advance... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 2,680 | -0,37 % | Cellectar Biosciences, Inc.: Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting | Approximately 80% Major Response Rate and Duration of Response Exceeding 16 Months in Subset Analysis of Patients Treated with Iopofosine I 131 Immediately Post-BTKi Therapy Plans to Initiate Phase... ► Artikel lesen | |
| CYTODYN | 0,192 | -8,57 % | CytoDyn Inc.: CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer's Disease | Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer's disease VANCOUVER, Washington, June 11... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,170 | +5,69 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports First Quarter 2026 Results and Provides Business Update | Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial Company to provide detailed data update from Phase 2 CRDF-004... ► Artikel lesen | |
| EMERGENT BIOSOLUTIONS | 7,220 | +1,40 % | Emergent BioSolutions Receives $64.5 Million Contract Modification for BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] to Support U.S. Biodefense Strategy | GAITHERSBURG, Md., May 28, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has been awarded a contract modification valued at approximately $64.5 million from the... ► Artikel lesen | |
| DENALI THERAPEUTICS | 23,650 | +1,24 % | DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth? | ||
| CEL-SCI | 1,140 | -5,00 % | CEL SCI CORP - 8-K, Current Report | ||
| CYTOKINETICS | 74,98 | +0,94 % | Cytokinetics, Incorporated: Cytokinetics Announces Three Late-Breaking Science Abstracts at the European Society of Cardiology (ESC) Congress 2026 | ||
| COHERUS ONCOLOGY | 1,399 | -3,38 % | Coherus Oncology, Inc.: Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI (toripalimab-tpzi) | REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) and Zumutor Biologics Inc. ("Zumutor"), an immuno-oncology biotech company, today announced a clinical... ► Artikel lesen | |
| CURIS | 4,570 | 0,00 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 03.07.2026 | Das Instrument OCI US00089H1068 ACS A.DE C.ADR 1/5/EO-,50 EQUITY wird cum Kapitalmassnahme gehandelt am 03.07.2026 und ex Kapitalmassnahme am 06.07.2026 The instrument OCI US00089H1068 ACS A.DE C.ADR... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 3,319 | +2,88 % | CytomX Therapeutics Inc.: CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer | - Expanded collaboration builds upon research momentum in developing next-generation bispecific immunotherapies using CytomX's PROBODY- and Regeneron's Veloci-Bi- platforms - - CytomX to receive... ► Artikel lesen | |
| FATE THERAPEUTICS | 2,652 | +3,19 % | Fate Therapeutics, Inc.: Fate Therapeutics Receives FDA Clearance of Investigational New Drug Application for FT839 Product Candidate | First-of-Kind, Dual-CAR T cell Targeting CD19 and CD38 for Comprehensive Elimination of Complex, Multi-System Autoimmune Disorders Advances into Phase 1/2 Clinical Development Novel 13-point edited... ► Artikel lesen |
EVOMMUNE INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 13,520 Euro und damit +2,19 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EVOMMUNE INC finden Sie auf Wallstreet Online.